Phosphagenics’ first commercialized pharmaceutical product is its TPM®/Diclofenac gel.

In November 2011, Phosphagenics announced a licensing agreement with Themis Medicare Pvt Ltd of India to manufacture and sell a diclofenac gel in India incorporating Phosphagenics’ TPM® drug delivery technology. In April 2013, Themis entered into a sub-licensing agreement with Novartis India to sell the TPM®/Diclofenac gel. Phosphagenics receives a royalty on sales of the products and supplies the TPM® raw material.

In early 2014, Novartis India launched the Voveran® TPM gel, and Themis launched the Instanac® TPM gel. Phosphagenics is actively seeking commercial partners interested in marketing this product in other geographies.